☆ 4.2 Review

Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review

DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

Related references

Note: Only part of the references are listed.

Article Plant Sciences

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Ke Hu et al.

Summary: The study found that the use of LH capsules in treating patients with Covid-19 significantly improved the symptom recovery rate, shortened the time to symptom relief, and had positive effects on the patients' imaging manifestations and clinical cure rate.

PHYTOMEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

Hassan Yousefi et al.

Summary: The outbreak of the novel coronavirus has caused a major global public health concern, with over 31 million cases confirmed and efforts being made to repurpose existing cancer drugs to treat COVID-19. These drugs target the viral replication cycle and immune response, offering a potential novel approach to combat the virus.

BIOCHEMICAL PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

Francesco Di Pierro et al.

Summary: Treatment with QP in COVID-19 patients can lead to faster virus clearance, reduced symptoms severity, and improved blood parameters, showing promising potential as a therapeutic intervention for the disease.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study

Francesco Di Pierro et al.

Summary: The study indicates that Quercetin Phytosome may have potential therapeutic effects for COVID-19 patients, reducing hospitalization and mortality rates. It is also shown to be safe and may have anti-fatigue and appetite-enhancing properties.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Review Chemistry, Medicinal

SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19

Ilaria Vicenti et al.

Summary: The current SARS-CoV-2 pandemic requires urgent prevention and treatment strategies. Repurposing drugs approved for other indications or successfully tested for safety and tolerability is an attractive strategy to quickly provide effective medication for severe cases. While vaccination is awaited, repurposed drugs could help treat severe cases, and improving knowledge of RdRp activity may aid in drug development for SARS-CoV-2 and future pandemics.

EXPERT OPINION ON THERAPEUTIC PATENTS (2021)

Add to Collection

Article Infectious Diseases

Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial

Fatemeh Roozbeh et al.

Summary: This trial aimed to evaluate the efficacy of sofosbuvir and daclatasvir for outpatients with mild COVID-19 infection, results showed no significant difference in symptoms after 7 days but a significant reduction in fatigue and dyspnoea patients in the sofosbuvir/daclatasvir arm after 1 month.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Infectious Diseases

A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Sabeena Ahmed et al.

Summary: Ivermectin, an FDA-approved anti-parasitic agent, was found to inhibit SARS-CoV-2 replication in vitro. A trial in Bangladesh showed that a 5-day course of ivermectin can promote viral clearance in adult patients with mild COVID-19.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial

Eduardo Lopez-Medina et al.

Summary: The study found that a 5-day course of ivermectin did not significantly improve the time to resolution of symptoms in adults with mild COVID-19, and does not support its use for treatment of mild COVID-19. Larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Integrative & Complementary Medicine

The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Zhijian Luo et al.

Summary: The study demonstrates that Xuebijing injection can effectively suppress the cytokine storm in severe COVID-19 patients by reducing the secretion of pro-inflammatory cytokines IL-6, IL-8, and TNF-??????, increasing lymphocyte levels, and decreasing CRP levels. However, Xuebijing did not significantly reduce the 28-day mortality rate.

EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Phillip D. Monk et al.

Summary: The study evaluated the efficacy and safety of using interferon beta-1a to treat COVID-19, with results showing that patients who received treatment had higher and faster recovery rates, providing potential evidence for further clinical trials.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Review Immunology

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Nikolaos C. Kyriakidis et al.

Summary: The new SARS-CoV-2 virus is rapidly spreading worldwide, causing the COVID-19 pandemic with more than 1.866 million deaths. Over 64 vaccine candidates are being developed globally, aiming to induce antibodies to prevent viral entry. Thirteen vaccine candidates are currently in Phase 3 clinical trials, showing promising progress towards approval for large-scale immunizations.

NPJ VACCINES (2021)

Add to Collection

Article Infectious Diseases

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Nurullah Okumus et al.

Summary: This study aimed to investigate the presence of gene mutations affecting ivermectin metabolism in patients with severe COVID-19 pneumonia, and evaluate the effectiveness and safety of ivermectin treatment. Clinical improvement rate was higher in the ivermectin group compared to the control group after 5 days of treatment. Ivermectin showed potential in increasing clinical recovery and improving prognostic laboratory parameters in severe COVID-19 patients, suggesting it could be considered as an alternative treatment option.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

Add to Collection

Article Health Care Sciences & Services

Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study

Xiaolong Xu et al.

Summary: Reduning injection may be effective and safe in patients with symptomatic COVID-19, showing faster resolution of symptoms, negative nucleic acid test conversion, shorter hospital stay, and quicker defervescence compared to controls.

ANNALS OF PALLIATIVE MEDICINE (2021)

Add to Collection

Article Virology

Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study

Sherief Abd-Elsalam et al.

Summary: Researchers conducted a study to evaluate the efficacy of ivermectin for COVID-19 treatment, finding that patients in the ivermectin group had a shorter hospital stay compared to the control group, although the difference was not statistically significant.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial

Kirti S. Pawar et al.

Summary: The study found that using curcumin/piperine treatment in COVID-19 can improve symptoms, reduce deterioration, and improve clinical outcomes. In addition, curcumin/piperine treatment also appears to shorten hospitalization for severe patients and reduce mortality.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Immunology

Critical Review of the Scientific Evidence and Recommendations in COVID-19 Management Guidelines

Jiaxing Xie et al.

Summary: Research shows that the quality of guidelines for COVID-19 management varies greatly, with few recommendations having evidence-based support.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Anesthesiology

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Lakshmi Mahajan et al.

Summary: The study found that a five-day course of remdesivir treatment did not lead to improvement in clinical outcomes for patients with moderate to severe COVID-19. There were no significant differences between the two groups in terms of mortality, time to recovery, and occurrence of adverse effects related to remdesivir.

INDIAN JOURNAL OF ANAESTHESIA (2021)

Add to Collection

Article Infectious Diseases

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents

Joshua Wolf et al.

Summary: This study suggests that there is currently no evidence supporting the use of monoclonal antibody therapy for treating COVID-19 in children or adolescents, despite the typically mild course of the disease in this population. Limited evidence of modest benefit in adults is available, but there is a risk of potential harm associated with infusion reactions or anaphylaxis.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)

Add to Collection

Article Endocrinology & Metabolism

Scientometric analyzing the output of researchers and organizations on COVID-19 for better conducting the scientific efforts: with a glance to endocrinology

Rasha Atlasi et al.

Summary: This study analyzed all publications related to COVID-19 in the Web of Science database, retrieving a total of 56,402 records and 309 hot papers, with 3 of them falling under the endocrinology category. The most common publication type was original papers, followed by editorial papers. The USA had the highest number of published documents, followed by China, while the British Medical Journal and the Journal of Medical Virology were the top sources of publications. Harvard University and The Lancet were highlighted as top organizations and journals in terms of scientific output and highly-cited papers in this field.

JOURNAL OF DIABETES AND METABOLIC DISORDERS (2021)

Add to Collection

Article Hematology

COVID-19 and its implications for thrombosis and anticoagulation

Jean M. Connors et al.

BLOOD (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin An Analysis of the World Health Organization Pharmacovigilance Database

Lee S. Nguyen et al.

CIRCULATION (2020)

Add to Collection

Editorial Material Medicine, Research & Experimental

The convalescent sera option for containing COVID-19

Arturo Casadevall et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

COVID-19 update: Covid-19-associated coagulopathy

Richard C. Becker

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

Add to Collection

Review Immunology

Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?

Harald Murck

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Nicholas J. Mercuro et al.

JAMA CARDIOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lin Ang et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Joshua Geleris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

Jieliang Wang et al.

AAPS PHARMSCITECH (2020)

Add to Collection

Article Microbiology

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19

Effat Davoudi-Monfared et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Pharmacology & Pharmacy

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Leon Caly et al.

ANTIVIRAL RESEARCH (2020)

Add to Collection

Review Biochemistry & Molecular Biology

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Victor J. Costela-Ruiz et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Add to Collection

Editorial Material Oncology

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Kamal S. Saini et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Immunology

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19

Jun Chen et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

Add to Collection

Article Pharmacology & Pharmacy

Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov

Yuhui Wang et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Mingzhong Xiao et al.

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Impact of the COVID-19 pandemic on clinical trials with drugs

Joerg Hasford

EXPERT OPINION ON DRUG SAFETY (2020)

Add to Collection

Article Medicine, General & Internal

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Hemalkumar B. Mehta et al.

BMJ OPEN (2020)

Add to Collection

Article Infectious Diseases

Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate

Mathieu Gendrot et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Infectious Diseases

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Anahita Sadeghi et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Hamideh Abbaspour Kasgari et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Girish N. Nadkarni et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Review Medicine, Research & Experimental

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

Mitra Abbasifard et al.

LIFE SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Study of ongoing registered clinical trials on COVID-19: a narrative review

Md Insiat Islam Rabby et al.

SAO PAULO MEDICAL JOURNAL (2020)

Add to Collection

Letter Medicine, Research & Experimental

Effects of Licorice on clinical symptoms and laboratory signs in moderately ill patients with pneumonia from COVID-19: A structured summary of a study protocol for a randomized controlled trial

Omid Safa et al.

TRIALS (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Virology, transmission, and pathogenesis of SARS-CoV-2

Muge Cevik et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Anup Agarwal et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Review Pharmacology & Pharmacy

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Chandan Sarkar et al.

FRONTIERS IN PHARMACOLOGY (2020)

Add to Collection

Editorial Material Endocrinology & Metabolism

Beneficial Effects of Anti-Oxidative Herbal Medicines in Diabetic Patients Infected with COVID-19: A Hypothesis

Ozra Tabatabaei-Malazy et al.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)

Add to Collection

Review Pharmacology & Pharmacy

COVID-19: A review of the proposed pharmacological treatments

Sarah Lam et al.

EUROPEAN JOURNAL OF PHARMACOLOGY (2020)

Add to Collection

Article Immunology

Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial

Hamid Rahmani et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

Add to Collection

Review Immunology

Immunological considerations for COVID-19 vaccine strategies

Mangalakumari Jeyanathan et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output

Mohamad Chahrour et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

Add to Collection

Review Chemistry, Medicinal

Repurposing Anti-Cancer Drugs for COVID-19 Treatment

Nicholas Borcherding et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2020)

Add to Collection

Review Immunology

Novel Platforms for the Development of a Universal influenza vaccine

Arun Kumar et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Review Pharmacology & Pharmacy

Clinical management and infection control of SARS: Lessons learned

Vincent C. C. Cheng et al.

ANTIVIRAL RESEARCH (2013)

Add to Collection

Article Multidisciplinary Sciences

A diverse range of gene products are effectors of the type I interferon antiviral response

John W. Schoggins et al.

NATURE (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.